Abstract: A retrospective cohort study was conducted including 3688 patients age 60 years or older without dementia enrolled in a depression screening study in primary care clinics. Information on antidepressant use and incident dementia during follow-up was retrieved from electronic medical records. The Cox proportional hazard models were used to compare the risk for incident dementia among 5 participant groups: selective serotonin re-uptake inhibitors (SSRI) only, non-SSRI only (non-SSRI), mixed group of SSRI and non-SSRI, not on antidepressants but depressed, and not on antidepressants and not depressed. SSRI and non-SSRI users had significantly higher dementia risk than the nondepressed nonusers (hazard ratio [HR] = 1.83, P = 0.0025 for SSRI users and HR = 1.50, P = 0.004 for non-SSRI users). In addition, SSRIs users had significantly higher dementia risk than non-users with severe depression (HR = 2.26, P = 0.0005). Future research is needed to confirm our results in other populations and to explore potential mechanism underlying the observed association.
D epression is common among elderly patients with prevalence rates around 10% to 15% for those living in the community. [1] [2] [3] Antidepressants are one of the most commonly prescribed drugs in the United States. In the 1990s, selective serotonin re-uptake inhibitors (SSRI) became the first line of drug treatment for depression, replacing tricyclic antidepressants (TCA). 4 Antidepressants have been hypothesized to have neuroprotective effects 5, 6 such as improved memory and cognition. 7 In addition, it has been suggested that treatment with SSRIs may improve cognitive function in patients with the Alzheimer's dementia, 8 although this is not consistent across studies. However, little is known about the long-term outcomes of antidepressant use in the elderly population with intact cognitive functions. Older adults are often underrepresented in clinical trials of antidepressants and the short duration of such trials are often limited to a few weeks or months. 9, 10 There have been few long-term studies to date investigating the association between antidepressant use and the risk of dementia.
Prior reports have pointed to potentially differential and complex relationships between different types of antidepressants and dementia risk. 11, 12 A nationwide study in Denmark found that the rate of developing dementia was higher among persons exposed to antidepressants compared with those unexposed to antidepressants. 11 However, in a follow-up study, the authors reported that continued long-term treatment with older antidepressants, such as TCAs, was associated with a reduced rate of dementia, whereas continued treatment with other classes of antidepressants including SSRIs was not. 13 A cohort study of postmenopausal women aged 65 to 79 years reported that antidepressant use at baseline and depression severity were associated with subsequent cognitive impairment. 12 In this study, we explore the association between antidepressant use and the incidence of dementia, using data from a longitudinal observational cohort study of elderly primary care patients.
METHODS

Study Population
From 1991 to 1993, all patients 60 years and older attending the primary care practice in the Wishard Health System were approached for participation in a depression screening study. A total of 4413 primary care patients were approached, of whom 115 refused; 57 were not able to complete the testing due to severe cognitive impairment; 284 patients were not eligible because they did not speak English, were in prison or a nursing home, or had a hearing impairment, leaving 3957 total enrolled patients. The methods and results of the depression screening program have been previously reported. 14, 15 Patients who were diagnosed with dementia before enrollment were excluded from this analysis, resulting in a total of 3688 patients. The study was approved by the Institutional Review Boards of Indiana University-Purdue University of Indianapolis.
Data Source
Medical history information from enrollment to December 31, 2010 was extracted from the Regenstrief Medical Record System. 16 
Antidepressant Use
Medication dispensing data were retrieved from the electronic medical records for any antidepressant dispensed including medication name, dispensing date, duration, and dose from enrollment through December 31, 2010 or the patient's last encounter with the health care system.
Study Endpoint
To avoid an immortal time bias 17 due to differences in the timing of antidepressant use, each subject's baseline was defined as the first date a patient was prescribed an antidepressant for those in the medication group. Baseline was defined as the date at enrollment for patients who were never prescribed antidepressants. Incident dementia was identified as the first date that each subject was assigned a new dementia diagnosis based on ICD-9 codes. Study endpoint was defined as the time of diagnosis for patients with incident dementia, and the time of the last outpatient primary care physician visit during follow-up for patients who were not diagnosed with dementia.
Statistical Analysis
To examine potential differential effects of SSRI and other antidepressants and also control for the effect of depression, we divided patients into 5 mutually exclusive groups. The first group consisted of patients who were prescribed only SSRIs throughout the follow-up period (group 1: SSRIs group). The second group consisted of participants who were prescribed only non-SSRI antidepressants throughout the follow-up period (group 2: nonSSRIs group). The third group consisted of participants who were prescribed both SSRIs as well as other types of antidepressants during follow-up (group 3: mixed group). The fourth group included participants who were not prescribed any antidepressant during follow-up but whose CESD scores at enrollment were Z16 or who had been diagnosed with depression before enrollment (group 4: nonusers with depression). The fifth group consisted of participants who were not prescribed antidepressants and had no significant symptoms of depression at enrollment (CESD score <16 at enrollment) (group 5: nonusers no depression).
Comparison of demographic characteristics and medical history among the 5 groups of participants were conducted using w 2 tests for categorical variables and analysis of variance for continuous variables. Cox proportional hazards models were used to examine whether antidepressant use was associated with dementia risk. Proportional hazard assumption was tested by including an interaction term with group indicator and time as timedependent covariate in the Cox model. Covariates such as age or comorbid conditions were adjusted at individual baseline with the exception of CESD and SPMSQ that were measured at enrollment. Backward model selection was used to identify potential covariates in the Cox models. As the baseline time of patients on antidepressants was after enrollment time, the 2 nonuser groups had longer follow-up time than the 3 antidepressant groups. To detect the influence from the differences in follow-up times, we conducted 3 sets of Cox models using 3 different censoring times in our analyses based on the quartile survival times (50%, 75%, and 100%) in the participants on antidepressants. The first set of models used 5-year follow-up as the censoring time that was the median survival time in the 3 antidepressants groups. The second set of models used 9-year censoring time and the third set of models used the entire 18 years as the follow-up length.
We also conducted a sensitivity analysis by increasing the threshold of CESD score from 16 to 24 in group 4 to compare dementia risk between severely depressed nonantidepressant participants and antidepressant users. In a second sensitivity analysis, we included medication possession ratio (MPR, defined as duration on medication divided by total time) for patients in the antidepressants groups to detect a dose-response relationship. SAS 9.3 was used for all analyses.
RESULTS
A total of 3688 patients were included in the analysis. The mean age at enrollment was 67.9 years (SD = 7.3), with 69.1% being women. There were 14.86% patients with CESD score Z16 and 5.04% with SPMSQ value >4 indicating cognitive impairment. The median follow-up from baseline to study endpoint was 5.1 years in the cohort. A total of 574 (15%) participants were diagnosed with incident dementia during the entire observation period, of whom 231 patients were diagnosed with incident dementia during the first 5-year observation period, and 373 dementia events were identified during the first 9 years of observation period.
In Table 1 , we included comparisons of demographic information and medical history at enrollment among the 5 patient groups. Years from enrollment to antidepressant use, number of dispensing and years on antidepressants for groups 1, 2, and 3 were also included. Although there were many differences among the 5 groups, the 3 antidepressant user groups and the nonuser but depressed group differed in proportions of women, African American participants, smokers, mean years of education, mean body mass index, and history of arthritis, chronic obstructive pulmonary disease, hypertension. These 4 depressed groups also differed significantly on mean age, mean CESD score, and cognitive scores. However, the SSRIs group (group 1) and the non-SSRI group (group 2) were similar in CESD and SPMSQ scores. The mixed group had higher rate of diagnosed depression at enrollment as well as longer antidepressant use and greater number of antidepressant dispensing when compared with the SSRI and non-SSRI groups (Table 1) . Table 2 included results from the Cox models with 3 different censoring times. In all 3 sets of models, participants who were on SSRIs (group 1) or non-SSRIs (group 2) during follow-up period had higher dementia risk than the depressed nonusers (group 4). No significant differences were found between mixed antidepressant users and nonusers who were not depressed or between depressed nonusers and not-depressed nonusers.
When we increased the requirement for depression severity from CESD of 16 or higher to 24 or higher in group 4, and compared each of the antidepressant user groups with the nonusers with severe depression (Table 3) , we found again that SSRI users had significantly higher dementia risk than nonusers with severe depression in all 3 sets of models with varying follow-up length (hazard ratio [HR] = 2.21, P = 0.01 in model 1; HR = 2.19, P = 0.003 in model 2; HR = 2.26, P = 0.001 in model 3). In addition, the difference between participants in the non-SSRI group and the severely depressed nonusers was marginally significant in the 9-year follow-up model (HR = 1.54, P = 0.05) and became significant in the 18-year follow-up model (HR = 1.62, P = 0.02). In sensitivity analysis of adjusting for MPR in the antidepressant groups, we found that both SSRIs and non-SSRI groups had significantly higher dementia risk than the mixed group (5-year model: HR = 2.653, P = 0.0053 for the SSRIs group; HR = 2.619, P = 0.0017 for the non-SSRIs group). In addition, higher MPR was associated with higher dementia risk (HR = 1.418 per 0.1 unit increase in MPR, P < 0.0001) indicating a dose-response relationship with dementia risk. Similar results were observed in the 9-year or 18-year follow-up model. We also conducted an additional sensitivity analysis by excluding participants with SPMSQ > 4 (indicating potential cognitive impairment) and obtained similar results.
DISCUSSION
In this elderly primary care patient cohort, we found that SSRIs users were at significantly higher risk for incident dementia when compared with not depressed nonusers and also when compared with nonusers with depression. Patients who were taking non-SSRIs also showed significantly higher risk for incident dementia when compared with nonusers without depression. Patients who took both SSRIs and non-SSRIs or who were depressed but not taking antidepressants showed no difference in dementia risk compared with nonusers who were not depressed. Few studies to date have investigated the association between antidepressant use and incidence of dementia. These studies report varying results depending on the types of antidepressants, length of treatment, and the comparison group. One Danish study showed that the rate of dementia decreased during periods of 2 or more prescriptions of older antidepressants compared with only 1 prescription of older antidepressants. 13 In contrast, continued use of SSRIs or newer non-SSRIs was not associated with decreased rate of dementia regardless of the subtype of dementia. Another analysis by the same group showed that people who purchased antidepressants once had an increased rate of dementia compared with persons unexposed to antidepressants. 11 A cohort study of postmenopausal women aged 65 to 79 years reported that antidepressant use at baseline, for both SSRI and TCA, and depression severity were associated with subsequent cognitive impairment when compared with nondepressed nonusers. 12 When antidepressant users were compared with depressed nonusers, the difference in risk for cognitive impairment was no longer significant.
One of the challenges in studying long-term outcomes in antidepressant users is untangling the effect of the medication from the potential effect of depression, the underlying condition for treatment. Previous studies have shown that late-life depression is associated with an increased risk for dementia, vascular dementia and the Alzheimer's disease. 18 Hence any comparisons of antidepressant users to nondepressed nonusers are subject to indication bias as the increased dementia risk could be due to depression, not the medication. As randomized trial of sufficient length comparing antidepressants to nonpharmacological interventions in depressed and nondepressed participants is likely to pose both design difficulties and raise ethical considerations, analysis of large observational cohort data may be the only way to address this question. In our analyses, by creating different groups of antidepressant users and dividing the nonusers into those with depression and another group without depression, we are able to separate the potential effects due to medication use and those due to both depression and antidepressant use. It has been hypothesized previously that antidepressants may be protective of dementia. A recent study in 23 young healthy volunteers aged 18 to 50 showed that the accumulation of amyloid-b in cerebrospinal fluid was slowed by 37% within hours with the treatment of citalopram (an SSRI) compared with placebo. 19 Other studies argued that antidepressants may have neuroprotective abilities by increasing the proliferation of neural progenitors in the hippocampus and prolonging the survival of these newborn neurons 5, 6 thus leading to improved cognition. 7 Some studies have reported the association between antidepressant use and increased hippocampus volume in nongeriatric subjects. [20] [21] [22] However, other neuroimaging studies have reported that antidepressant use was significantly associated with smaller hippocampus volume. 23 A recent population-based study of older adults without dementia showed that antidepressants use was significantly associated with smaller total brain, smaller hippocampal, and larger white matter hyperintensity volume, whereas high CES-D scores were not significantly associated with any of the brain measures. 24 A common limitation of these imaging studies is that they were cross-sectional in nature, and most were conducted in younger participants, thus making it difficult to infer whether the observed association was due to prolonged depression or antidepressant use.
Other studies actually suggest that antidepressant therapy may worsen the course of cognitive decline in certain patients. A recent study demonstrated that treatment of behavioral symptoms in patients with Alzheimer's Disease (AD) with SSRI antidepressants resulted in improved scores on agitation rating, but worsened scores on cognitive functions. 25 Similarly, another recent study suggested that antidepressants use in patients with early stages of AD and Lewy body dementia worsened cortical thinning, especially the parahippocampal regions. 26 Thus, while much of the neurogenesis studies with antidepressants were seen in younger depressed subjects, quite different mechanisms may be at play in the elderly, especially those who are already in the prodromal stage of dementia.
The potential biological mechanism underlying the higher dementia risk in SSRI users is not yet clear. One animal study has demonstrated upregulation of the GPR39 Zn 2 + -sensing receptor protein level after SSRI treatment but not with TCA. 27 As it has been proposed that either low zinc or excessive zinc may lead to neurofibrillary tangles, a primary mark of the Alzheimer's disease and cognitive impairment, 28, 29 a potential link between SSRI use and dementia may be through the zinc pathway.
A somewhat surprising finding in our results was that patients in the mixed group were not at increased risk of dementia despite of showing higher depression diagnosis rate, longer time on antidepressants and greater number of dispensing than the SSRI and non-SSRI groups. The use of antidepressant combination is a popular strategy in practice to treat those patients with treatment resistant depression. 30 Hence it is possible that patients in the mixed group were resistant to antidepressant treatment and perhaps also immune to other deleterious brain effects of antidepressants.
Our study has a number of strength. The cohort is relatively large with long follow-up period. The use of electronic medical records eliminates recall and potential attrition bias. A comprehensive list of medical conditions was available from electronic medical record so that relevant covariates can be included in the analysis.
Our findings may be subject to biases and artifacts that are inherent to most observational studies. For example, one possible explanation for the observed results may be reverse causation, that is doctors either consciously or unconsciously were more likely to prescribe SSRIs rather than TCAs to older adults with cognitive impairment as there is a widespread recognition that TCAs have higher anticholinergic adverse effects 31, 32 and if prescribers were attempting to avoid these effects, they may differentially prescribe SSRIs to older adults with cognitive impairment. A previous study has shown that depressed patients with mild cognitive impairment were more likely to develop dementia. 33 Although we excluded patients with dementia at baseline and conducted a sensitivity analysis excluding patients with SPMSQ scores >4, it is possible that participants with nondementia cognitive impairment were still included in our analysis and the co-existence of depression with mild cognitive impairment may account for the higher dementia risk. However, since we also found that the SSRI group had a higher dementia risk compared with the nonusers with severe depression, the inclusion of potential mild cognitive impairment subjects in the analyses is unlikely to account for the results.
Another potential issue in our result is ascertainment bias, that is persons with depression may be more likely to receive an early diagnosis of dementia. However, 2 subgroups of patients with depression, that is those who received mixed types of antidepressants or those not receiving antidepressants, were found not at higher risk of dementia, making the ascertainment bias an unlikely explanation for our results. Providers could have also mistakenly diagnosed early cognitive impairment as depression.
The validity of using ICD-9 codes for dementia diagnosis using both inpatient and outpatient records was found to be high with sensitivity of 85.5 and specificity of 85.9. 34, 35 In our study, we used ICD-9 codes contained in inpatient, outpatient, and emergency room records. The definition for other comorbid conditions using ICD-9 codes has been used before by various studies with established validity. [36] [37] [38] One difference in our study from previous studies is that a significant number of our subjects were African Americans. There are racial differences in response to antidepressant regimen, with African Americans generally showing significantly lower response rates than Caucasians. 39 Furthermore, depression in the elderly, especially in African Americans, is often associated with cerebrovascular disease which is also a major risk factor for cognitive decline and dementia. 40 Our study also has a number of other limitations. The medical records did not include depression severity measures after study enrollment. Hence it is not possible for us to determine whether the higher dementia risk in SSRI users was due to the lack of depression control. Similarly, no uniform dementia severity was available in the medical record system to adjust for dementia severity. In addition, we do not have information on antidepressant use before participant's enrollment. Thus, it is not possible for us to separate the typical depression patients from patients with late-life depression. Another limitation is the use of dispensing data as a measure of medication exposure, which assumes that subjects consumed medication as prescribed.
In addition, no information on the treatment indication for antidepressant use was available. Hence it is possible that some antidepressants dispensed were dispensed for nondepression indications such as pain control.
In summary, we found that SSRIs users in this elderly primary care cohort followed over 18 years were at significantly higher risk for incident dementia when compared with not depressed nonusers and also when compared with nonusers with depression. Given the potential for various confounding and the limited data on depression and cognitive measures, our results should be considered hypothesis generating. It will be important to see whether our results are confirmed in other studies with more detailed information on depression and cognitive function. Future studies are also needed to identify potential mechanism underlying the observed association between SSRI use and dementia risk in the elderly population.
